🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 2

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 2 of 20
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Feb 26, 2024 at 7:14 PM#6

One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

43 21TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 40 others
Reply Quote Save Share Report
laura_annarbor
Member
189
890
Dec 2024
Ann Arbor, MI
Feb 26, 2024 at 8:30 PM#7

One thing that is still open after EndoResFellow’s answer:

How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?

44 22emily_PDX, Dr.SleepRoch, laura_annarbor and 41 others
Reply Quote Save Share Report
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Feb 26, 2024 at 9:46 PM#8
labquiet_amy said:
A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.

There is a second half to this that has not been said yet. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

That is the short version; the long version is somebody else's post.

45 23MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 42 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Feb 26, 2024 at 11:02 PM#9

Closing the loop on my own question.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

46 24Dr.PulmRoch, maya_sedona, stefan_berlin and 43 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Feb 27, 2024 at 5:07 AM#10
VendorMark said:
The gap between trial results and real-world results is consistent and it is not fraud.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

46 19NurseLeah_Nash, gary_naperville, sean_dublin and 43 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register